繁體中文 
English 
Recent Posts
- The Investigational Oral Anti-Cancer Drug CVM-1118 Receives NMPA Approval to Initiate a Phase II Clinical Trial for Intermediate-Stage Liver Cancer in China.
- 本公司抗癌口服研發中新藥 CVM-1118用於治療中期肝癌，獲中國國家藥品監督管理局核准執行第二期臨床試驗。
- TaiRx’s New Drug CVM-1118 Granted Orphan Drug Designation for Pancreatic Neuroendocrine Tumors (PNETs), Securing Seven Years of Market Exclusivity in the U.S.
- 台睿新藥CVM-1118取得胰腺神經內分泌腫瘤(PNETs)孤兒藥資格，未來上市享美國7年市場專賣獨佔權
- 本公司股務代理機構營業處所遷址公告
Post Archive
- 2025 年 11 月
- 2025 年 2 月
- 2025 年 1 月
- 2024 年 11 月
- 2024 年 7 月
- 2024 年 5 月
- 2023 年 1 月
- 2022 年 12 月
- 2022 年 5 月
- 2020 年 12 月
- 2020 年 11 月
- 2020 年 3 月
- 2019 年 12 月
- 2019 年 8 月
- 2019 年 1 月
- 2018 年 10 月
- 2018 年 4 月
- 2018 年 3 月
- 2017 年 10 月
- 2017 年 8 月
- 2017 年 6 月
- 2016 年 6 月
- 2016 年 3 月
- 2015 年 12 月
- 2015 年 9 月
- 2015 年 7 月
- 2015 年 5 月
- 2014 年 3 月
- 2014 年 1 月
- 2013 年 12 月
Catogery Tags
Connect With Us
-
TaiRx, Inc. and BioHealth Innovation, Inc. Form TaiRx US to Develop and Commercialize Therapeutics and Precision Medicine Diagnostics- Joint venture to focus on the Nodal protein, a previously untargeted and critical mediator of aggressive cancer progression and treatment resistance
TaiRx, Inc and BioHealth Innovation, Inc. (BHI) announc…
-
A major milestone for cancer drug development in Taiwan! CVM-1118 approved by the US FDA to start Phase II clinical study in the US.
TaiRx’s CVM-1118 small molecule cancer drug received US…
-
A first in Taiwan! In collaboration with Taiwanese API and drug product manufacturers, TaiRx produced the first domestically manufactured selenium trace element drug in Taiwan and was approved by the Taiwan FDA.
TaiRx, Inc. (6580) announces today that its new injecti…
-
TaiRx published study results of serum GPx-3 protein levels and associated bioactivity in healthy subjects and sepsis patients in Clinica Chimica Acta.
Lee WJ, Chen YL, Chu YW, Chien DS. Comparison of glutat…
-
TaiRx and Northwestern University Ann & Robert H. Lurie Children’s Hospital completed exclusive licensing deal for global development and market rights using Nodal protein as new biomarker to detect malignant tumor also for the treatment of various metastatic cancer.
TaiRx Announces License Agreement with Northwestern Uni…
-
TaiRx held a pre-IPO institutional investors’ conference and announced the listing on Taiwan Emerging Market on the 20th of June.
TaiRx shows its potential in new cancer drug developmen…
-
TaiRx presents CVM-1118 Phase I Clinical Trial Progress at ASCO
TaiRx, Inc. (6580) publishes its Phase I clinical trial…
-
Science reported TaiRx’s CVM-1118 as the first drug entering clinical trial, inhibiting the formation of vasculogenic mimicry in cancer.
This issue of Science magazine (June 17, 2016) featured…
-
